ライフサイエンスコーパス: interstitial lung disease

1 ry fibrosis (IPF) is a progressive and fatal interstitial lung disease.

2 ease manifestations, including RA-associated interstitial lung disease.

3 nsion is a common and deadly complication of interstitial lung disease.

4 ngest in recipients with cystic fibrosis and interstitial lung disease.

5 patient presenting with clinical evidence of interstitial lung disease.

6 tment of pulmonary hypertension secondary to interstitial lung disease.

7 of autoantibody present and the severity of interstitial lung disease.

8 attenuates lung injury in a murine model of interstitial lung disease.

9 ew therapeutic approach for the treatment of interstitial lung disease.

10 may facilitate investigation of subclinical interstitial lung disease.

11 ing neonatal respiratory failure and chronic interstitial lung disease.

12 even reverse, fibrogenesis in patients with interstitial lung disease.

13 hic pulmonary fibrosis, a progressive lethal interstitial lung disease.

14 hological correlates to characteristic human interstitial lung disease.

15 mast cells, than many of the other forms of interstitial lung disease.

16 temic steroids, and 1 patient died of severe interstitial lung disease.

17 inflammation, destructive skin lesions, and interstitial lung disease.

18 of active alveolitis and scleroderma-related interstitial lung disease.

19 iarrhea, but 2% of patients died of presumed interstitial lung disease.

20 ients whose disease course is complicated by interstitial lung disease.

21 degree of activity of the systemic sclerosis-interstitial lung disease.

22 duced hypoxia is an index of the severity of interstitial lung disease.

23 n and may play a role in the pathogenesis of interstitial lung disease.

24 tacrolimus are efficacious in patients with interstitial lung disease.

25 ns in and possible genetic predisposition to interstitial lung disease.

26 nt morbidity and mortality seen in pediatric interstitial lung disease.

27 care hospital, and 11 patients with chronic interstitial lung disease.

28 en in the sex-adjusted incidence rate of all interstitial lung disease.

29 k for a previously unrecognized occupational interstitial lung disease.

30 in many clinical conditions, particularly in interstitial lung disease.

31 ulated in the setting of scleroderma-related interstitial lung disease.

32 lophosphamide), with most due to progressive interstitial lung disease.

33 tment-related by the investigator was due to interstitial lung disease.

34 ted with rheumatoid arthritis complicated by interstitial lung disease.

35 d changes in lung physiology consistent with interstitial lung disease.

36 r autoantibodies, inflammatory arthritis and interstitial lung disease.

37 t role in the pathogenesis of SSc-associated interstitial lung disease.

38 or both chronic obstructive lung disease and interstitial lung disease.

39 antisynthetase syndrome and myositis-related interstitial lung disease.

40 iques to molecularly phenotype patients with interstitial lung disease.

41 ted for nonconnective tissue disease-related interstitial lung disease.

42 IL-22 represents a novel pathway involved in interstitial lung disease.

43 that may play a role in the pathogenesis of interstitial lung diseases.

44 nts as chronic respiratory illness mimicking interstitial lung diseases.

45 to be a useful marker of disease activity in interstitial lung diseases.

46 er iBALT forms in patients with a variety of interstitial lung diseases.

47 and understanding of the pathogenesis of the interstitial lung diseases.

48 e fluid similar to other CD8 T cell-mediated interstitial lung diseases.

49 singly recognized as a complication of these interstitial lung diseases.

50 e proportion of rheumatic disease-associated interstitial lung diseases.

51 t concepts regarding the management of these interstitial lung diseases.

52 to centers specializing in the evaluation of interstitial lung diseases.

53 Lung fibrosis is the hallmark of the interstitial lung diseases.

54 .8%), idiopathic pulmonary fibrosis (22.9%), interstitial lung disease (15.6%), and cystic fibrosis (

55 D, 360; alpha-1-antitrypsin deficiency, 127; interstitial lung disease, 195; cystic fibrosis, 69; oth

56 roup more often had radiographic evidence of interstitial lung disease (48% versus 13% of the ACA gro

57 ive patient with Blau syndrome who exhibited interstitial lung disease, a feature historically consid

58 In other conditions, such as tuberculosis, interstitial lung disease, acute lung aspiration, and ac

59 Plains, New England, and South Atlantic for interstitial lung disease; along the southern half of th

60 due to telomere dysfunction and humans with interstitial lung disease also accumulate excess chitin

61 ge, 43 [16] years) including 4 patients with interstitial lung disease and 3 patients with cutaneous

62 ge, 43 [16] years) including 4 patients with interstitial lung disease and 3 patients with cutaneous

63 Cyclophosphamide has been used to treat the interstitial lung disease and a placebo-controlled trial

64 evels of SP-D are increased in patients with interstitial lung disease and acute respiratory distress

65 CMO is a lifesaving option for patients with interstitial lung disease and acute respiratory failure

66 retrospective analysis of all patients with interstitial lung disease and acute respiratory failure

67 Patients with interstitial lung disease and acute respiratory failure

68 An association between calcinosis and both interstitial lung disease and anti-MDA-5 autoantibodies

69 ation in the human ITGA3 gene, causing fatal interstitial lung disease and congenital nephrotic syndr

70 rt findings in 70 patients with both diffuse interstitial lung disease and either polymyositis (PM) o

71 apeutic strategies in scleroderma-associated interstitial lung disease and in idiopathic pulmonary fi

72 rfactant proteins are found in patients with interstitial lung disease and lung cancer, but their pat

73 important factor in the pathogenesis of the interstitial lung disease and lymphoproliferative disord

74 idence in the multidisciplinary diagnosis of interstitial lung disease and may prove useful in the di

75 (aSS) is characterized by the association of interstitial lung disease and myositis with anti-tRNA sy

76 study drug by the investigators, one due to interstitial lung disease and one as a result of multior

77 Pulmonary diseases, comprising interstitial lung disease and pulmonary arterial hyperte

78 n the chemotherapy plus cetuximab group (one interstitial lung disease and pulmonary embolism, one br

79 ational Classification of Diseases codes for interstitial lung disease and surgical lung biopsies.

80 ents with these antibodies often have severe interstitial lung disease and the poorest prognosis, oft

81 ians continue to define the various types of interstitial lung disease and to evaluate the roles of b

82 variety of pulmonary diseases including the interstitial lung diseases and asthma.

83 A number of lung diseases, including many interstitial lung diseases and HIV infection, are associ

84 nary fibrosis is the most common form of the interstitial lung diseases and is characterized by chron

85 D-208 may be therapeutically useful in human interstitial lung diseases and pulmonary fibrosis.

86 f gene expression signatures to classify the interstitial lung diseases and to understand pathogenic

87 clerosis-related pulmonary hypertension with interstitial lung disease, and 67 IPAH).

88 d to pulmonary hypertension in patients with interstitial lung disease, and effective treatment optio

89 that included congenital nephrotic syndrome, interstitial lung disease, and epidermolysis bullosa.

90 system represents a new model of autoimmune interstitial lung disease, and establishes a closer link

91 sculopathy, he experienced recurrent fevers, interstitial lung disease, and failure to thrive.

92 stitial pneumonia, respiratory bronchiolitis-interstitial lung disease, and from patients without IIP

93 mofetil for progressive scleroderma-related interstitial lung disease, and the present preference fo

94 into the causes of other forms of pediatric interstitial lung diseases, and may suggest novel treatm

95 on of a "pulmonary-muscle" syndrome in which interstitial lung disease antedated the onset of myopath

96 -section CT findings usually associated with interstitial lung disease are frequently seen in asympto

97 studies of systemic sclerosis patients with interstitial lung disease are yielding promising data th

98 The interstitial lung diseases are a heterogeneous group of

99 Children's interstitial lung diseases are rare diffuse lung disease

100 atous glomerular and interstitial nephritis, interstitial lung disease, arterial hypertension, hypert

101 thic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease associated with aging that is

102 ry lymphoneogenesis, although a component of interstitial lung disease associated with autoimmune dis

103 cal spectrum, pathogenesis, and treatment of interstitial lung disease associated with inflammatory m

104 Whether the prognosis of interstitial lung disease associated with rheumatic dise

105 eature of numerous lung disorders, including interstitial lung diseases, asthma, and chronic obstruct

106 There was a basilar predominance of interstitial lung disease at CT.

107 ng biopsy samples from patients with various interstitial lung diseases at 11 hospitals in North Amer

108 th chronic obstructive pulmonary disease and interstitial lung disease but not cancer.

109 odies were also found in patients with other interstitial lung diseases but were not associated with

110 ial pneumonia, and respiratory bronchiolitis-interstitial lung disease, but not patients without IIP,

111 y a role in the etiology and pathogenesis of interstitial lung disease, but transcriptional signature

112 Silicosis is an interstitial lung disease caused by the inhalation of cr

113 tosis (LAM) is a progressive and often fatal interstitial lung disease characterized by a diffuse pro

114 tosis (LAM) is a progressive and often fatal interstitial lung disease characterized by a diffuse pro

115 Lymphangioleiomyomatosis (LAM) is an interstitial lung disease characterized by invasion and

116 These autoimmune mice had interstitial lung disease characterized by lymphocytic a

117 Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by severe, progr

118 endous progress in the approach to childhood interstitial lung diseases (chILD), with particular reco

119 at our institution between 2004 and 2014 for interstitial lung disease, chronic obstructive pulmonary

120 In addition to the historical interstitial lung diseases (coal worker's pneumoconiosis

121 Pediatric interstitial lung disease comprises a diverse group of r

122 oing thoracic surgery for reasons other than interstitial lung disease (control) (n = 78) and from pa

123 oing thoracic surgery for reasons other than interstitial lung disease (control) or from patients wit

124 onitis, respiratory bronchiolitis-associated interstitial lung disease, cryptogenic organizing pneumo

125 , chronic obstructive pulmonary disease, and interstitial lung disease; development of vaccines to pr

126 were similar to the 221 patients with other interstitial lung disease diagnoses (1.46 [0.24]) after

127 -0.63]; p=0.0048), but not for patients with interstitial lung disease diagnoses other than idiopathi

128 Pulmonary fibrosis is a kind of devastating interstitial lung disease due to the limited therapeutic

129 Interstitial lung diseases encompass a wide range of dif

130 Establishing the etiology of fibrosing interstitial lung disease (FILD) remains a clinical chal

131 the recent medical literature pertaining to interstitial lung disease found in association with syst

132 Interstitial lung disease frequently complicates the rhe

133 Forty-five experts in interstitial lung disease from 14 countries participated

134 onal cohort study, we enrolled patients with interstitial lung disease from Dallas, TX (primary cohor

135 iciency (CVID) and granulomatous/lymphocytic interstitial lung disease (GLILD) are at high risk for e

136 The extent of interstitial lung disease, ground-glass opacification, e

137 atients with symptomatic scleroderma-related interstitial lung disease had a significant but modest b

138 Patients with SSc in whom PH and significant interstitial lung disease had been excluded at baseline

139 A work-related interstitial lung disease has been diagnosed in workers

140 trials in patients with myositis-associated interstitial lung disease have not occurred, new observa

141 Diagnosis is difficult because other interstitial lung diseases have similar radiological and

142 g been implicated in the pathogenesis of the interstitial lung disease, idiopathic pulmonary fibrosis

143 30.4+/-6.8 [SD] yrs) and seven patients with interstitial lung disease (ILD) (3 male and 4 female; ag

144 high-throughput flow cytometry (FC) data and interstitial lung disease (ILD) - a systemic sclerosis (

145 itis/dermatomyositis (PM/DM) with or without interstitial lung disease (ILD) also produced these anti

146 The mechanisms underlying dyspnea in interstitial lung disease (ILD) and chronic obstructive

147 ssification (DPO) in patients with fibrosing interstitial lung disease (ILD) and determine whether th

148 the most pressing challenges associated with interstitial lung disease (ILD) are how best to define,

149 mon and specific signatures across end-stage interstitial lung disease (ILD) cases, (2) characterize

150 onary fibrosis (IPF) is a progressive, fatal interstitial lung disease (ILD) characterized by abnorma

151 n the lung tissue of patients suffering from interstitial lung disease (ILD) due to mutations in the

152 he diagnosis and management of patients with interstitial lung disease (ILD) has been a subject of de

153 Interstitial lung disease (ILD) has been recognized as a

154 nge of occupational exposures on subclinical interstitial lung disease (ILD) has not been studied.

155 e prevalence and clinical characteristics of interstitial lung disease (ILD) in a large cohort of pat

156 actant protein C; SFTPC) have been linked to interstitial lung disease (ILD) in children and adults.

157 tion, diagnosis, treatment, and prognosis of interstitial lung disease (ILD) in children.

158 es (chILD), with particular recognition that interstitial lung disease (ILD) in infants is often dist

159 and understanding of the entities that cause interstitial lung disease (ILD) in infants.

160 RATIONALE: Interstitial lung disease (ILD) is a heterogeneous group

161 tatins) in the development or progression of interstitial lung disease (ILD) is controversial.

162 Interstitial lung disease (ILD) is the leading cause of

163 n systemic sclerosis (SSc; scleroderma), and interstitial lung disease (ILD) is the most common pulmo

164 onary fibrosis (IPF) is a progressive, fatal interstitial lung disease (ILD) of unknown etiology.

165 ic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) of unknown origin charac

166 Interstitial lung disease (ILD) with pulmonary fibrosis

167 Interstitial lung disease (ILD), a leading cause of morb

168 cal role in systemic sclerosis (SSc)-related interstitial lung disease (ILD), and imatinib is a poten

169 tained from patients with PPH, patients with interstitial lung disease (ILD), and normal control subj

170 tomography (HRCT) is commonly used to assess interstitial lung disease (ILD), relatively little is kn

171 nfluencing survival in children with chronic interstitial lung disease (ILD), we extracted specific c

172 cy in myositis including those patients with interstitial lung disease (ILD), whereas mycophenolate m

173 whether this association is attributable to interstitial lung disease (ILD).

174 rved in patients with clinically significant interstitial lung disease (ILD).

175 sociated with cancer, neurodegeneration, and interstitial lung disease (ILD).

176 l hypertension [PAH]) or in association with interstitial lung disease (ILD).

177 tor antagonist, as a therapy for SSc-related interstitial lung disease (ILD).

178 erial hypertension [PAH]) or associated with interstitial lung disease (ILD).

179 ng function in patients with scleroderma and interstitial lung disease (ILD).

180 sitis/dermatomyositis (PM/DM) complicated by interstitial lung disease (ILD).

181 pathway are important in the pathogenesis of interstitial lung disease (ILD).

182 The rate of progression of most interstitial lung diseases (ILD) is unpredictable.

183 Interstitial lung diseases (ILDs) are associated with ox

184 Progressive fibrotic interstitial lung diseases (ILDs) are characterised by m

185 Interstitial lung diseases (ILDs) are characterized by i

186 clerosis-related pulmonary hypertension with interstitial lung disease imposes a greater pulmonary va

187 t radiography and CT, respectively, revealed interstitial lung disease in 47 (90%) and 51 (98%) of th

188 angerhans'-cell histiocytosis is an uncommon interstitial lung disease in adults.

189 ause lethal respiratory distress at birth or interstitial lung disease in childhood.

190 the development of granulomatous-lymphocytic interstitial lung disease in CVID), and an increased ris

191 Mutations in the SFTPC gene associated with interstitial lung disease in human patients result in mi

192 s of alveolar hemorrhage as the mechanism of interstitial lung disease in MPA.

193 l-transfer RNA synthetase (HisRS, Jo-1) with interstitial lung disease in patients with myositis led

194 Interstitial lung disease in patients with SSc is less e

195 ABCA3 mutations cause some types of interstitial lung disease in pediatric patients.

196 Several histologic lesions cause interstitial lung disease in rheumatic diseases, includi

197 polymorphism was found to be associated with interstitial lung disease in the general population.

198 whether this polymorphism is associated with interstitial lung disease in the general population.

199 g of the phenotype and prognosis that define interstitial lung disease in the setting of myositis and

200 urgical lung biopsies performed annually for interstitial lung disease in the United States, two-thir

201 suggested a genetic basis for some forms of interstitial lung diseases in children.

202 ne encoding SP-C are associated with chronic interstitial lung diseases in newborns, older children,

203 shes usual interstitial pneumonia from other interstitial lung diseases in surgical lung biopsy sampl

204 onchiolar involvement may be seen in several interstitial lung diseases, including hypersensitivity p

205 The pathogenesis of interstitial lung diseases, including its most common fo

206 y, subacute and chronic HP may mimic several interstitial lung diseases, including nonspecific inters

207 of normal adult lung or other proliferative interstitial lung diseases, indicating that the expressi

208 BCA3, have been shown to result in pediatric interstitial lung diseases inherited in autosomal-domina

209 Interstitial lung disease is common in the rheumatic dis

210 lity after elective surgical lung biopsy for interstitial lung disease is just under 2% but significa

211 nesis, prognosis, and treatment of pediatric interstitial lung disease is limited.

212 Respiratory bronchiolitis-interstitial lung disease is now commonly diagnosed with

213 0.77]) and connective tissue disease-related interstitial lung disease (kappaw=0.73 [0.68-0.78]); mod

214 - mice, a strain that spontaneously develops interstitial lung disease-like lung pathology with age.

215 and other diseases (asthma, smoking-related interstitial lung diseases) linked to OPN overexpression

216 US medical centres with scleroderma-related interstitial lung disease meeting defined dyspnoea, pulm

217 d to determine the spectrum and frequency of interstitial lung disease mimicking Pneumocystis pneumon

218 dyspnoea (n=1), failure to thrive (n=1), and interstitial lung disease (n=1).

219 s in the carfilzomib group (pneumonia [n=2], interstitial lung disease [n=1], septic shock [n=1], and

220 ns with nonconnective tissue disease-related interstitial lung disease (nCTD-ILD).

221 SV hospitalization, including malformations, interstitial lung disease, neuromuscular disease, liver

222 Four patients developed interstitial lung disease of grade 3 or higher, with one

223 lon flocking plant in Rhode Island developed interstitial lung disease of unknown cause.

224 pulmonary fibrosis (IPF), a chronic diffuse interstitial lung disease of unknown cause.

225 pulmonary fibrosis (IPF), a chronic diffuse interstitial lung disease of unknown etiology.

226 Idiopathic pulmonary fibrosis is a chronic interstitial lung disease of unknown etiology; its epide

227 lmonary fibrosis is a heterogeneous group of interstitial lung diseases of unknown cause that is asso

228 ology, dyspnea, and evidence of inflammatory interstitial lung disease on examination of bronchoalveo

229 stemic sclerosis, most commonly occurring as interstitial lung disease or as pulmonary hypertension.

230 rker's lung" required histologic evidence of interstitial lung disease (or lavage evidence of lung in

231 s with COPD, alpha-1-antitrypsin deficiency, interstitial lung disease, or cystic fibrosis before and

232 ook place in the management of patients with interstitial lung diseases over the last century.

233 on in the pathogenesis of systemic sclerosis-interstitial lung disease, particularly in the early pha

234 s on developing safe and effective drugs for interstitial lung diseases, particularly for idiopathic

235 oproteinase-7 (MMP-7) has been implicated in interstitial lung disease pathobiology and proposed as a

236 nti-inflammatory mediators may be central to interstitial lung disease pathogenesis, which presents p

237 tial pneumonia and respiratory bronchiolitis/interstitial lung disease patient groups.

238 ification of genes responsible for pediatric interstitial lung diseases provides the opportunity for

239 (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), cryptogenic organizi

240 a (DIP)/respiratory bronchiolitis-associated interstitial lung disease (RBILD) (17%).

241 Forty patients with interstitial lung disease referred to our intensive care

242 osis pathogenesis, a chronic and progressive interstitial lung disease, remain elusive.

243 Many of the interstitial lung diseases represent a diagnostic and th

244 unrelated families and 44 sporadic cases of interstitial lung disease revealed five other mutations

245 atistically significant correlations between interstitial lung disease score at CT and age or percent

246 Treatment of these interstitial lung diseases should take into account the

247 l lymphoproliferative disorders, infections, interstitial lung diseases, smoking, and congenital or d

248 Twenty patients with SSc, 15 with interstitial lung disease (SSc-ILD) alone, and 5 with pu

249 Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are thought to have

250 onary fibrosis (IPF) and scleroderma-related interstitial lung disease (SSc-ILD).

251 patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

252 , chronic obstructive pulmonary disease, and interstitial lung diseases such as idiopathic pulmonary

253 There was less HRQL benefit in interstitial lung disease than in cystic fibrosis.

254 s an underrecognized form of immune-mediated interstitial lung disease that results from repeated exp

255 Hypersensitivity pneumonitis is an interstitial lung disease that results from repeated pul

256 ions between the diagnosis of obstructive or interstitial lung disease, two diagnostic breathing test

257 inflammation characterized by vasculopathy, interstitial lung disease, ulcerative skin lesions, and

258 inical data of patients who presented to the interstitial lung disease unit of the Royal Brompton and

259 Interstitial lung disease was common and was equally dis

260 A score for the degree of interstitial lung disease was derived at both radiograph

261 2 of 16 SRP-positive PM patients (13%), and interstitial lung disease was noted in 3 of 13 SRP-posit

262 ontributes to the fibrotic response in human interstitial lung disease, we studied lung tissue, bronc

263 ophosphamide for treatment of SSc-associated interstitial lung disease were evaluated.

264 ibrosis or connective tissue disease-related interstitial lung disease were risk factors for increase

265 alter the progression of scleroderma-related interstitial lung disease when compared with placebo.

266 fibrosis (IPF) is a chronic and progressive interstitial lung disease, wherein transforming growth f

267 sclerosis or limited systemic sclerosis and interstitial lung disease who were treated with HSCT as

268 ssive intervention in African Americans with interstitial lung disease will improve outcomes.

269 e.g., asthma with "work/effort" and "tight," interstitial lung disease with "work/effort" and "rapid"

270 Treatment of scleroderma-related interstitial lung disease with mycophenolate mofetil for

271 a common, progressive, and invariably lethal interstitial lung disease with no effective therapy.

272 nary fibrosis (IPF) is a form of progressive interstitial lung disease with unknown etiology.

273 he occurrence of familial cases of pediatric interstitial lung diseases with the onset of symptoms de

274 fibrosing alveolitis (CFA) is a progressive interstitial lung disease, with a median survival of 3 t

275 s, infections, smoking-related diseases, and interstitial lung diseases, with a focus on lymphangiole

276 study we selected 117 patients with fibrotic interstitial lung disease without a typical usual inters